Q
Quisette P. Janssen
Researcher at Erasmus University Rotterdam
Publications - 22
Citations - 675
Quisette P. Janssen is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: FOLFIRINOX & Medicine. The author has an hindex of 5, co-authored 12 publications receiving 170 citations. Previous affiliations of Quisette P. Janssen include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P. Janssen,Stefan Buettner,Mustafa Suker,Berend R. Beumer,Pietro Addeo,Philippe Bachellier,Nathan Bahary,Tanios Bekaii-Saab,Maria Antonietta Bali,Marc G. Besselink,Brian A. Boone,Ian Chau,Stephen Clarke,Mary Dillhoff,Bassel F. El-Rayes,Jessica M. Frakes,Derek Grose,Peter J. Hosein,Nigel B. Jamieson,Ammar A. Javed,Khurum Khan,Kyu Pyo Kim,Song Cheol Kim,Sunhee S. Kim,Andrew H. Ko,Jill Lacy,Georgios A. Margonis,Martin D. McCarter,Colin J. McKay,Eric A. Mellon,Sing Yu Moorcraft,Ken Ichi Okada,Alessandro Paniccia,Parag J. Parikh,Niek A. Peters,Hans Rabl,Jaswinder S. Samra,Christoph Tinchon,Geertjan van Tienhoven,Eran van Veldhuisen,Andrea Wang-Gillam,Matthew J. Weiss,Johanna W. Wilmink,Hiroki Yamaue,Marjolein Y.V. Homs,Casper H.J. van Eijck,Matthew H.G. Katz,Bas Groot Koerkamp +47 more
TL;DR: This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate, which need to be assessed in a randomized trial.
Journal ArticleDOI
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Eva Versteijne,Jacob L van Dam,Mustafa Suker,Quisette P. Janssen,Karin B. C. Groothuis,Janine M Akkermans-Vogelaar,Marc G. Besselink,Bert A. Bonsing,Jeroen Buijsen,Olivier R. Busch,Geert-Jan Creemers,Ronald M. van Dam,Ferry A.L.M. Eskens,Sebastiaan Festen,Jan Willem B. de Groot,Bas Groot Koerkamp,Ignace H. J. T. de Hingh,Marjolein Y.V. Homs,Jeanin E. van Hooft,Emile D Kerver,Saskia A C Luelmo,Karen J. Neelis,Joost J. Nuyttens,G. Paardekooper,Gijs A. Patijn,Maurice J.C. van der Sangen,Judith de Vos-Geelen,Johanna W. Wilmink,Aeilko H. Zwinderman,Cornelis J. A. Punt,Geertjan van Tienhoven,Casper H.J. van Eijck +31 more
TL;DR: Neoadjuvant gem citabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adenovation in resectables and borderline resectable pancreatic cancer.
Journal ArticleDOI
Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
Quisette P. Janssen,Stefan Buettner,Mustafa Suker,Georgios A. Margonis,Alessandro Paniccia,Bassel F. El-Rayes,Nathan Bahary,Ian Chau,Peter J. Hosein,Andrew H. Ko,Jill Lacy,Nigel B. Jamieson,Christoph Tinchon,Kyu-Pyo Kim,Marc G. Besselink,Johanna W. Wilmink,Marjolein Y.V. Homs,Casper H.J. van Eijck,Matthew H.G. Katz,Bas Groot Koerkamp +19 more
TL;DR: FOLFIRINOX is the standard treatment of patients with metastatic pancreatic cancer and its effectiveness in the neoadjuvant setting in patients with (borderline) resectable pancreati...
Journal ArticleDOI
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment
Stijn van Roessel,Eran van Veldhuisen,Sjors Klompmaker,Quisette P. Janssen,Mohammed Abu Hilal,Adnan Alseidi,Adnan Alseidi,A. Balduzzi,Gianpaolo Balzano,Claudio Bassi,Frederik Berrevoet,Morgan Bonds,Olivier R. Busch,Giovanni Butturini,Marco Del Chiaro,Kevin C. Conlon,Massimo Falconi,Isabella Frigerio,Giuseppe Fusai,Johan Gagnière,Oonagh Griffin,Thilo Hackert,Asif Halimi,Ulla Klaiber,Knut Jørgen Labori,Giuseppe Malleo,Marco Vito Marino,Michael Bau Mortensen,A Nikov,Mickael Lesurtel,Tobias Keck,Jörg Kleeff,Rupaly Pande,Per Pfeiffer,D. Pietrasz,Keith J. Roberts,Antonio Sa Cunha,Roberto Salvia,Oliver Strobel,Timo Tarvainen,Patrick M.M. Bossuyt,Hanneke W. M. van Laarhoven,Johanna W. Wilmink,Bas Groot Koerkamp,Marc G. Besselink +44 more
TL;DR: Adjuvant chemotherapy after neoadjuvant FOLFIRINOX and resection of pancreatic cancer was associated with improved survival only in patients with pathology-proven node-positive disease, and future randomized studies should be conducted to confirm this finding.
Journal ArticleDOI
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Quisette P. Janssen,J.L. van Dam,Bert A. Bonsing,H. Bos,Koop Bosscha,P. P. L. O. Coene,C.H.J. van Eijck,I.H.J.T. de Hingh,Tom M. Karsten,M. van der Kolk,Gijs A. Patijn,M. Liem,H.C. van Santvoort,O. J. L. Loosveld,J. de Vos-Geelen,B.M. Zonderhuis,Marjolein Y.V. Homs,G. van Tienhoven,M.G. Besselink,Johanna W. Wilmink,B. Groot Koerkamp +20 more
TL;DR: The PREOPANC-2 trial as discussed by the authors investigated whether neoadjuvant FOLFIRINOX improves overall survival compared with single-agent chemotherapy regimens in patients with resectable and borderline-rescittable pancreatic cancer.